ALLMedicine Atopic Dermatitis Center

Jun 3rd, 2020 - Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). To investigate the efficacy and safety of abrocitinib ...

Jun 2nd, 2020 - Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. To investigate patient characteristics, treatment aspects, effectiveness and safety of up to 84 weeks of dupilumab treatment. An observational prospectiv...

Jun 2nd, 2020 - Royal jelly (RJ), a creamy substance secreted by honeybees, is the exclusive diet for queen bee differentiation and life maintenance. RJ has been used in cosmetics, beverages, medicines, and supplements worldwide. However, allergy is a concerning ...

Jun 1st, 2020 - Psoriasis (PS) and atopic dermatitis (AD) are common inflammatory skin diseases characterized by an imbalance in specific T cell subsets, resulting in a specific cytokine profile in patients. Obtaining models closely resembling both pathologies is...

Jun 1st, 2020 - One-year real-world clinical effectiveness, safety and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.|2020|Uchida H,Kamata M,Kato A,Mizukawa I,Watanabe A,|

Jun 24th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Jun 24th, 2019 - Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema and was formerly known as Besnier prurigo. It is the most common form of dermatitis. Atopi...

Jun 3rd, 2019 - Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People ...

Mar 17th, 2019 - This clinical report updates and replaces a 2008 clinical report from the American Academy of Pediatrics, which addressed the roles of maternal and early infant diet on the prevention of atopic disease, including atopic dermatitis, asthma, and foo...

Apr 20th, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

Jun 3rd, 2020 - Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). To investigate the efficacy and safety of abrocitinib ...

Jun 2nd, 2020 - Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. To investigate patient characteristics, treatment aspects, effectiveness and safety of up to 84 weeks of dupilumab treatment. An observational prospectiv...

Jun 2nd, 2020 - Royal jelly (RJ), a creamy substance secreted by honeybees, is the exclusive diet for queen bee differentiation and life maintenance. RJ has been used in cosmetics, beverages, medicines, and supplements worldwide. However, allergy is a concerning ...

Jun 1st, 2020 - Psoriasis (PS) and atopic dermatitis (AD) are common inflammatory skin diseases characterized by an imbalance in specific T cell subsets, resulting in a specific cytokine profile in patients. Obtaining models closely resembling both pathologies is...

Jun 1st, 2020 - One-year real-world clinical effectiveness, safety and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.|2020|Uchida H,Kamata M,Kato A,Mizukawa I,Watanabe A,|

May 26th, 2020 - The Food and Drug Administration has approved dupilumab for children aged 6-11 years with moderate to severe atopic dermatitis, the manufacturers announced. The new indication is for children "whose disease is not adequately controlled with topica...

Apr 3rd, 2020 - PARIS (Reuters) - Healthcare companies Sanofi and Regeneron announced on Friday more encouraging results for their Dupixent product used to treat severe atopic dermatitis, often commonly known as eczema. The companies said that Dupixent Phase 3 da...

Apr 2nd, 2020 - Screening for depression in patients with atopic dermatitis is a vital task that’s woefully neglected – and dermatologists aren’t doing any better a job of it than primary care physicians, Jonathan I. Silverberg, MD, PhD, declared in a video prese.

Mar 26th, 2020 - LAHAINA, HAWAII – Novel topical medications are in the works that will address the longstanding unmet need for a Food and Drug Administration–approved noncorticosteroid topical for use in pediatric atopic dermatitis, Lawrence F. Eichenfield, MD, r.

Mar 23rd, 2020 - Click to read. Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that affects approximately 10% of US children.